Improving the methodologic and ethical validity of best supportive care studies in oncology: Lessons from a systematic review

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5476-5486

  Cherny, Nathan I ^a   Abernethy, Amy P ^a   Strasser, Florian ^a   Sapir, Rama ^a   Currow, David ^a   Zafar, S Yousuf ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTITUSSIVE AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; LOMUSTINE; LORAZEPAM; MELATONIN; METHOTREXATE; MITOMYCIN; NAVELBINE; OCTREOTIDE; PACLITAXEL; PANITUMUMAB; PEMETREXED; TIPIFARNIB; TOPOTECAN; VINBLASTINE; VINDESINE;

ACCURACY; ADVANCED CANCER; BEST SUPPORTIVE CARE; BIBLIOGRAPHIC DATABASE; BILE DUCT CANCER; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; EDITOR; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; INSTITUTIONAL REVIEW; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL ETHICS; MESOTHELIOMA; META ANALYSIS; METHODOLOGY; NUTRITIONAL SUPPORT; PAIN; PANCREAS CANCER; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RESEARCH ETHICS; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL PSYCHOLOGY; STANDARDIZATION; STOMACH CANCER; SURVIVAL TIME; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VALIDITY; ARTICLE; INFORMATION RETRIEVAL; LITERATURE; NEOPLASM; ONCOLOGY; STANDARD;

CLINICAL TRIALS AS TOPIC; HUMANS; INFORMATION STORAGE AND RETRIEVAL; MEDICAL ONCOLOGY; META-ANALYSIS AS TOPIC; NEOPLASMS; REVIEW LITERATURE AS TOPIC;

EID: 73949113876     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9592     Document Type: Review

References (129)

1. MacDonald N: Best supportive care. Cancer Prev Control 2:191-192, 1998
2. Cullen M: 'Best supportive care' has had its day. Lancet Oncol 2:173-175, 2001
3. Ahmed N, Ahmedzai S, Vora V, et al: Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 2:CD003445, 2004
4. Zafar SY, Currow D, Abernethy AP: Defining best supportive care. J Clin Oncol 26:5139-5140, 2008
5. Sapir R, Catane R, Cherny NI: Cancer pain: Knowledge and attitudes of physicians in Israel. J Pain Symptom Manage 17:266-276, 1999
6. Von Roenn JH, Cleeland CS, Gonin R, et al: Physician attitudes and practice in cancer pain management: A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119:121-126, 1993
7. Grossman SA, Sheidler VR, Swedeen K, et al: Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 6:53-57, 1991
8. Yennurajalingam S, Zhang T, Bruera E: The impact of the palliative care mobile team on symptom assessment and medication profiles in patients admitted to a comprehensive cancer center. Support Care Cancer 15:471-475, 2007
9. Dhillon N, Kopetz S, Pei BL, et al: Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11:191-197, 2008
10. Feyer P, Kleeberg UR, Steingraber M, et al: Frequency of side effects in outpatient cancer care and their influence on patient satisfaction: A prospective survey using the PASQOC questionnaire. Support Care Cancer 16:567-575, 2008
11. Homsi J, Walsh D, Rivera N, et al: Symptom evaluation in palliative medicine: Patient report vs systematic assessment. Support Care Cancer 14: 444-453, 2006
12. Osta BE, Palmer JL, Paraskevopoulos T, et al: Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 11:51-57, 2008
13. Fadul N, Elsayem A, Palmer JL, et al: Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med 10:1146-1152, 2007
14. Kochhar R, Legrand SB, Walsh D, et al: Opioids in cancer pain: Common dosing errors. Oncology (Williston Park) 17:571-575, 2003; discussion 575-576, 579
15. Cherny NI, Ho MN, Bookbinder M, Fahey, et al: Cancer pain: Knowledge and attitudes of physicians at a cancer center. Proc Am Soc Clin Oncol 13:434, 1994 (abstr 1490)
16. Lagman R, Rivera N, Walsh D, et al: Acute inpatient palliative medicine in a cancer center: Clinical problems and medical interventions - A prospective study. Am J Hosp Palliat Care 24:20-28, 2007
17. Pigott C, Pollard A, Thomson K, et al: Unmet needs in cancer patients: Development of a supportive needs screening tool (SNST). Support Care Cancer 17:33-45, 2008
18. Li J, Girgis A: Supportive care needs: Are patients with lung cancer a neglected population? Psychooncology 15:509-516, 2006
19. Cherny NI, Catane R: Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: Report on a survey by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer 98:2502-2510, 2003
20. Emanuel EJ, Fairclough D, Clarridge BC, et al: Attitudes and practices of US oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med 133:527-532, 2000
21. Hilden JM, Emanuel EJ, Fairclough DL, et al: Attitudes and practices among pediatric oncologists regarding end-of- life care: Results of the 1998 American Society of Clinical Oncology survey. J Clin Oncol 19:205-212, 2001
22. Buss MK, Lessen DS, Sullivan AM, et al: Survey of oncology fellows' end-of-life training. J Clin Oncol 23:737s, 2005 (suppl; abstr 8032)
23. Field MJ, Cassel EK (eds): Approaching Death: Improving Care at the End of Life. Washington, DC, National Academy Press, 1997
24. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964. Ferney-Voltaire, France, World Medical Association, 1964
25. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Amended by the 29th World Medical Association General Assembly, Tokyo, Japan, October 1975. Ferney-Voltaire, France, World Medical Association, 1975
26. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Amended by 35th World Medical Association General Assembly, Venice, Italy, October 1983. Ferney-Voltaire, France, World Medical Association, 1983
27. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Amended by 41st World Medical Association General Assembly, Hong Kong, Japan, September 1989. World Medical Association, 1989
28. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Amended by the 48th World Medical Association General Assembly, Somerset West, Republic of South Africa, October 1996. Ferney-Voltaire, France, World Medical Association, 1996
29. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Amended by the 52nd World Medical Association General Assembly, Edinburgh, Scotland, October 2000. Ferney-Voltaire, France, World Medical Association, 2000
30. World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects - Amended by the 59th World Medical Association General Assembly, Seoul, Korea, October 2008. Ferney-Voltaire, France, World Medical Association, 2008
31. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001
32. Boutron I, Moher D, Altman DG, et al: Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: Explanation and elaboration. Ann Intern Med 148:295-309, 2008
33. Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical? JAMA 283:2701-2711, 2000
34. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
35. Brown J, Thorpe H, Napp V, et al: Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 23:7417-7427, 2005
36. O'Brien ME, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24: 5441-5447, 2006
37. Jassem J, Ramlau R, Santoro A, et al: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698-1704, 2008
38. Rao S, Cunningham D, de Gramont A, et al: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950-3957, 2004
39. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
40. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
41. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
42. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer. J Clin Oncol 8:1301-1309, 1990
43. Cellerino R, Tummarello D, Guidi F, Isidori, et al: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-smallcell lung cancer. J Clin Oncol 9:1453-1461, 1991
44. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
45. Leighl NB, Shepherd FA, Kwong R, et al: Economic analysis of the TAX 317 trial: Docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 20:1344-1352, 2002
46. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small-cell lung cancer: A randomized trial with quality of life as the primary outcome - UK NSCLC Gemcitabine Group on non-small-cell lung cancer. Br J Cancer 83:447-453, 2000
47. Cascinu S, Del Ferro E, Catalano G: A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 71:97-101, 1995
48. Starling N, Tilden D, White J, et al: Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 96:206-212, 2007
49. Di Maio M, Perrone F, Gallo C, et al: Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 89:1013-1021, 2003
50. Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71:587-591, 1995
51. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small-cell lung cancer: Does chemotherapy make a difference? Cancer 63:1271-1278, 1989
52. Ganz PA, Haskell CM, Figlin RA, et al: Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index-Cancer. Cancer 61:849-856, 1988
53. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
54. Lissoni P, Barni S, Ardizzoia A, et al: A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 73:699-701, 1994
55. Glimelius B, Hoffman K, Sjoden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600, 1996
56. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997
57. Glimelius B, Hoffman K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189-190, 1994
58. Cartei G, Cartei F, Cantone A, et al: Cisplatincyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 85:794-800, 1993
59. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92: 1074-1080, 2000
60. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
61. Muers MF, Stephens RJ, Fisher P, et al: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 371:1685-1694, 2008
62. Cunningham D, Pyrhonen S, James RD, Punt, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
63. 62a. Cunningham D, Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy: V301 Study Group. Semin Oncol 26:6-12. 1999 (1 suppl 5)
64. Helsing M, Bergman B, Thaning L, et al: Quality of life and survival in patients with advanced non-small-cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: A multicentre randomised phase III trial - Joint Lung Cancer Study Group. Eur J Cancer 34:1036-1044, 1998
65. Thongprasert S, Sanguanmitra P, Juthapan W, et al: Relationship between quality of life and clinical outcomes in advanced non-small-cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24:17-24, 1999
66. Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small-cell lung cancer (NSCLC). Lung Cancer 27:145-157, 2000
67. Spiro SG, Rudd RM, Souhami RL, et al: Chemotherapy versus supportive care in advanced non-small-cell lung cancer: Improved survival without detriment to quality of life. Thorax 59:828-836, 2004
68. Brodowicz T, Krzakowski M, Zwitter M, et al: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small-cell lung cancer: A phase III trial. Lung Cancer 52:155-163, 2006
69. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
70. Cellerino R, Tummarello D, Porfiri E, et al: Non-small-cell lung cancer (NSCLC): A prospective randomized trial with alternating chemotherapy CEP/MEC versus no treatment. Eur J Cancer Clin Oncol 24:1839-1843, 1988
71. Leung WT, Shiu WC, Pang JC, et al: Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 49:321-326, 1992
72. Lissoni P, Barni S, Ardizzoia A, et al: Randomized study with the pineal hormone melatonin versus supportive care alone in advanced non-small-cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 49:336-339, 1992
73. Dancey J, Shepherd FA, Gralla RJ, et al: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 43:183-194, 2004
74. Mallinson CN, Rake MO, Cocking JB, et al: Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial. BMJ 281:1589-1591, 1980
75. Barni S, Lissoni P, Cazzaniga M, et al: A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 52:243-245, 1995
76. Lissoni P, Barni S, Fossati V, et al: A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer 3:194-197, 1995
77. Saunders C: The Management of Terminal Disease. London, United Kingdom, Arnold Publishers, 1978
78. World Health Organization: Cancer Pain Relief. Geneva, Switzerland, World Health Organization, 1986
79. World Health Organization: Cancer Pain Relief and Palliative Care. Geneva, Switzerland, World Health Organization, 1990
80. Doyle D, Hanks GW, MacDonald N, eds: Oxford Textbook of Palliative Medicine (ed 1). Oxford, United Kingdom, Oxford University Press, 1993
81. Gysels M, Higginson IJ: Improving supportive and palliative care for adults with cancer: Research Evidence Manual. London, United Kingdom, National Institute for Clinical Excellence, 2004
82. Lorenz KA, Lynn J, Dy SM, et al: Evidence for improving palliative care at the end of life: A systematic review. Ann Intern Med 148:147-159, 2008
83. Doyle D, Hanks G, Cherny N, Callman K: Oxford Textbook of Palliative Medicine (ed 3). Oxford, United Kingdom, Oxford University Press, 2005
84. Chapter 64: Supportive care and quality of life, in DeVita VT, Lawrence TS, Rosenberg SA, et al (eds): Cancer: Principles and Practice of Oncology (ed 8). Philadelphia, PA, Lippincott Williams & Wilkins, 2008, pp 2757-2856
85. American Medical Association: Good care of the dying patient: Council on Scientific Affairs, American Medical Association. JAMA 275:474-478, 1996
86. Morrison RS, Meier DE: Clinical practice: Palliative care. N Engl J Med 350:2582-2590, 2004
87. Foley K, Gelband H: Improving Palliative Care for Cancer: Summary and Recommendations. Washington, DC, National Academies Press, 2001
88. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines: Palliative Care V1. 2009, http://www.nccn.org/professionals/ physician-qls/ PDF/palliative.pdf
89. National Quality Forum: National Framework and Preferred Practices for Palliative and Hospice Care: A Consenus Report. Washington, DC, National Quality Forum, 2007
90. National Institute for Clinical Excellence (NICE): Improving Supportive and Palliative Care for Adults with Cancer: The manual. London, United Kingdom, National Health Service, 2004, p 204
91. Palliative Care Australia: Standards for Providing Quality Palliative Care for all Australians. Canberra, Australia, Palliative Care Australia, 2005
92. Naeim A, Dy SM, Lorenz KA, et al: Evidencebased recommendations for cancer nausea and vomiting. J Clin Oncol 26:3903-3910, 2008
93. Walling A, Lorenz KA, Dy SM, et al: Evidence-based recommendations for information and care planning in cancer care. J Clin Oncol 26:3896-3902, 2008
94. Dy SM, Lorenz KA, Naeim A, et al: Evidencebased recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26: 3886-3895, 2008
95. Dy SM, Asch SM, Naeim A, et al: Evidencebased standards for cancer pain management. J Clin Oncol 26:3879-3885, 2008
96. Hopewell S, Altman DG, Moher D, et al: Endorsement of the CONSORT Statement by high impact factor medical journals: A survey of journal editors and journal 'Instructions to Authors.' Trials 9:20, 2008
97. Emanuel EJ, Wendler D, Killen J, et al: What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infec Dis 189:930-937, 2004
98. Varmus H: Testimony on the value of clinical research by harold varmus before the Senate Committee on Labor and Human Resources, Subcommittee on Public Health and Safety, October 9,1997. http://www.hhs.gov/asl/testify/t971009a.html
99. von Gunten CF: Oncologists and end-of-life care. J Palliat Med 11:813, 2008
100. Jackson VA, Mack J, Matsuyama R, et al: A qualitative study of oncologists' approaches to endof-life care. J Palliat Med 11:893-906, 2008
101. Pantilat SZ, Billings JA: Prevalence and structure of palliative care services in California hospitals. Arch Intern Med 163:1084-1088, 2003
102. Gelfman LP, Meier DE, Morrison RS: Does palliative care improve quality? A survey of bereaved family members. J Pain Symptom Manage 36:22-28, 2008
103. Dy SM, Shugarman LR, Lorenz KA, et al: A systematic review of satisfaction with care at the end of life. J Am Geriatr Soc 56:124-129, 2008
104. Finlay IG, Higginson IJ, Goodwin DM, et al: Palliative care in hospital, hospice, at home: Results from a systematic review. Ann Oncol 13:257-264, 2002 (suppl 4)
105. Goodwin DM, Higginson IJ, Edwards AG, et al: An evaluation of systematic reviews of palliative care services. J Palliat Care 18:77-83, 2002
106. Higginson IJ, Finlay I, Goodwin DM, et al: Do hospital-based palliative teams improve care for patients or families at the end of life? J Pain Symptom Manage 23:96-106, 2002
107. Harding R, Higginson IJ: What is the best way to help caregivers in cancer and palliative care? A systematic literature review of interventions and their effectiveness. Palliat Med 17:63-74, 2003
108. American Society of Clinical Oncology: Cancer care during the last phase of life. J Clin Oncol 16:1986-1996, 1998
109. Smith TJ, Schnipper LJ: The American Society of Clinical Oncology program to improve end-oflife care. J Palliat Med 1:221-230, 1998
110. Ferris FD, Bruera E, Cherny N, et al: Palliative cancer care a decade later: Accomplishments, the need, next steps-From the American Society of Clinical Oncology. J Clin Oncol 27:3052-3058, 2009
111. Cherny NI, Catane R, Kosmidis P: ESMO takes a stand on supportive and palliative care. Ann Oncol 14:1335-1337, 2003
112. Brennan F: Palliative care as an international human right. J Pain Symptom Manage 33:494-499, 2007
113. Agrawal M, Danis M: End-of-life care for terminally ill participants in clinical research. J Palliat Med 5:729-737, 2002
114. Mann H, Djulbegovic B: Choosing a control intervention for a randomised clinical trial. BMC Med Res Methodol 3:7, 2003
115. Emanuel EJ, Wood A, Fleischman A, et al: Oversight of human participants research: Identifying problems to evaluate reform proposals. Ann Intern Med 141:282-291, 2004
116. Office of the Inspector General: Institutional Review Boards: A Time for Reform. Washington, DC, Department of Health and Human Services, DHHS publication OEI-97-00193, 1998. http:// oig.hhs.gov/oei/reports/oei-01-97-00193. pdf
117. International Conference On Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Expert Working Group. Guideline For Good Clinical Practice: Current Step 4 version, June 10, 1996. Geneva, Switzerland, 1996, p 59
118. Jefferson T, Rudin M, Brodney Folse S, et al: Editorial peer review for improving the quality of reports of biomedical studies. Cochrane Database Syst Rev 2:MR000016, 2007
119. Liberati A, Himel HN, Chalmers TC: A quality assessment of randomized control trials of primary treatment of breast cancer. J Clin Oncol 4:942-951, 1986
120. Soares HP, Daniels S, Kumar A, et al: Bad reporting does not mean bad methods for randomised trials: Observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 328:22-24, 2004
121. Haynes RB: What kind of evidence is it that evidence-based medicine advocates want health care providers and consumers to pay attention to? BMC Health Serv Res 2:3, 2002
122. Higgins JPT, Altman DG: Chapter 8: Assessing risk of bias in included studies, in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions 2008. http://www .cochrane-handbook.org/
123. Djulbegovic B, Clarke M: Ethical issues in the reporting of clinical trials. JAMA 286:1577-1578, 2001
124. Huguier M, Barrier A, Valinas R, et al: Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer. Hepatogastroenterology 48:875-878, 2001
125. Shinchi H, Takao S, Noma H, et al: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53:146-150, 2002
126. O'Brien ME, Watkins D, Ryan C, et al: A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: The MED trial. Ann Oncol 17:270-275, 2006
127. Buccheri GF, Ferrigno D, Curcio A, et al: Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small-cell lung cancer and stable disease after two or three cycles of MACC: Results of a randomized prospective study. Cancer 63:428-432, 1989
128. Kaasa S, Lund E, Thorud E, et al: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small-cell lung cancer. Cancer 67:2443-2447, 1991
129. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 366:1527-1537, 2005